Aquestive Therapeutics Inc (AQST)
5.15
-0.37
(-6.70%)
USD |
NASDAQ |
Nov 04, 16:00
5.05
-0.10
(-1.94%)
Pre-Market: 08:37
Aquestive Therapeutics Net Income (Quarterly): -2.745M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | -2.745M |
March 31, 2024 | -12.83M |
December 31, 2023 | -8.111M |
September 30, 2023 | -2.035M |
June 30, 2023 | -5.792M |
March 31, 2023 | 8.068M |
December 31, 2022 | -12.35M |
September 30, 2022 | -12.54M |
June 30, 2022 | -16.30M |
March 31, 2022 | -13.22M |
December 31, 2021 | -28.94M |
September 30, 2021 | -14.56M |
June 30, 2021 | -12.37M |
March 31, 2021 | -14.67M |
December 31, 2020 | -20.37M |
Date | Value |
---|---|
September 30, 2020 | -16.55M |
June 30, 2020 | -2.334M |
March 31, 2020 | -16.53M |
December 31, 2019 | -12.64M |
September 30, 2019 | -18.41M |
June 30, 2019 | -20.47M |
March 31, 2019 | -14.73M |
December 31, 2018 | -13.94M |
September 30, 2018 | -15.04M |
June 30, 2018 | -36.49M |
March 31, 2018 | 4.099M |
December 31, 2017 | -10.04M |
September 30, 2017 | 8.451M |
June 30, 2017 | -5.897M |
March 31, 2017 | -1.457M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-28.94M
Minimum
Dec 2021
8.068M
Maximum
Mar 2023
-11.41M
Average
-12.64M
Median
Dec 2019
Net Income (Quarterly) Benchmarks
ACADIA Pharmaceuticals Inc | 33.39M |
Rockwell Medical Inc | 0.343M |
Cormedix Inc | -2.777M |
Geovax Labs Inc | -5.064M |
Myomo Inc | -1.122M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 20.10M |
Total Expenses (Quarterly) | 20.04M |
EPS Diluted (Quarterly) | -0.03 |
Enterprise Value | 409.12M |
Gross Profit Margin (Quarterly) | 77.48% |
Profit Margin (Quarterly) | -13.66% |
Earnings Yield | -7.07% |
Normalized Earnings Yield | -6.835 |